Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review - GlobalData - Company Reports

Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review

Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review - GlobalData - Company Reports
Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review
Published Nov 29, 2016
43 pages — Published Nov 29, 2016
Price US$ 125.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company which discovers and develops a pipeline of differentiated therapeutics for orphan indications. The company's pipeline products include Glybera, XEN801, sodium channel inhibitor and TV-45070. Xenon through its core platform, Extreme Genetic, discovers various validated drug targets through the study of rare human diseases with extreme traits, including channelopathies, diseases caused by mutations in ion channels. Its platform comprises full complement of in-house capabilities for human genetics, small molecule drug discovery, and for pre-clinical and clinical development.

GlobalData's Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Xenon Pharmaceuticals Inc Key Recent Developments:

Nov 03,2016: Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Sep 27,2016: Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
Aug 03,2016: Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
May 10,2016: Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
Apr 04,2016: Xenon Names Dr. Raymond J. Winquist as Head, Translational Research


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage,

  
Source:
Document ID
GDPH132674FA
Country
Industry
Ticker
XENE=CA
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Section 1 - About the Company41
Xenon Pharmaceuticals Inc - Key Facts51
Xenon Pharmaceuticals Inc - Key Employees61
Xenon Pharmaceuticals Inc - Major Products and Services71
Xenon Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data83
  Xenon Pharmaceuticals Inc, Pipeline Products by Therapy Area81
  Xenon Pharmaceuticals Inc, Pipeline Products by Development Phase92
Xenon Pharmaceuticals Inc - History111
Xenon Pharmaceuticals Inc - Locations And Subsidiaries121
  Head Office121
Section 2 Company Analysis131
Company Overview131
Xenon Pharmaceuticals Inc - Key Competitors141
Section 3 Company Financial Ratios151
Financial Ratios - Capital Market Ratios151
Financial Ratios - Annual Ratios162
Performance Chart181
Financial Performance181
Financial Ratios - Interim Ratios191
Financial Ratios - Ratio Charts201
Section 4 Company s Lifesciences Financial Deals and Alliances212
  Xenon Pharmaceuticals Inc, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016211
  Xenon Pharmaceuticals Inc, Pharmaceuticals &Healthcare, Deals By Type, 2010 to YTD 2016221
Xenon Pharmaceuticals Inc, Recent Deals Summary231
Section 5 Company s Recent Developments241
Nov 03, 2016: Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update242
Sep 27, 2016: Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors261
Aug 03, 2016: Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update272
May 10, 2016: Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update292
Apr 04, 2016: Xenon Names Dr. Raymond J. Winquist as Head, Translational Research311
Mar 31, 2016: Xenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference321
Mar 08, 2016: Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update332
Feb 09, 2016: Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery351
Jan 11, 2016: Xenon Outlines Key Milestones for 2016361
Nov 10, 2015: Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update372
Section 6 Appendix395
  Methodology391
  Ratio Definitions394
  About GlobalData431
  Contact Us431
  Disclaimer431

Table Of Contents

GlobalData - Company Reports—GlobalData is an industry analysis specialist, providing business information products and services. These high quality company reports are created via a large research and analysis capability, drawing from extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
GlobalData - Company Reports. "Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review" Nov 29, 2016. Alacra Store. Sep 22, 2019. <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Xenon-Pharmaceuticals-Inc-XENE-Financial-Analysis-Review-2087-63593>
  
APA:
GlobalData - Company Reports. (2016). Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review Nov 29, 2016. New York, NY: Alacra Store. Retrieved Sep 22, 2019 from <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Xenon-Pharmaceuticals-Inc-XENE-Financial-Analysis-Review-2087-63593>
  
US$ 125.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Company Profiles from one place.